Soleno Therapeutics’ Vykat XR Exceeds Sales Expectations

Maham Fatima

Mon, Jul 21, 2025, 4:15 AM 2 min read

Soleno Therapeutics Inc. (NASDAQ:SLNO) is 1 of the champion performing mid headdress stocks truthful acold successful 2025. On July 10, Soleno Therapeutics announced that the income of its caller Prader-Willi illness drug, called Vykat XR, are exceeding Wall Street expectations. Vykat XR is the archetypal approved attraction for the insatiable hunger associated with Prader-Willi syndrome and was approved successful the US connected March 26 earlier this year.

For the 3 months ending June 30, Soleno anticipates nett gross from Vykat XR income to beryllium betwixt $31 and $33 million. Since its approval, the institution has received ~646 “start forms” from 295 physicians, which shows beardown archetypal demand. While the quarterly show reappraisal is ongoing and estimates could change, Stifel expert James Condulis noted that these preliminary numbers are well-above capitalist expectations.

A enactment of biopharmaceutical products connected a laboratory support waiting to beryllium tested.

Prader-Willi syndrome is simply a uncommon familial information that affects an estimated 10,000 to 20,000 radical successful the US, characterized by behavioral and cognitive symptoms, astir notably an all-consuming hunger (hyperphagia). Before Vykat XR, the absorption of the illness typically progressive supportive attraction and quality maturation hormone.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is simply a clinical-stage biopharmaceutical institution that develops and commercializes caller therapeutics for the attraction of uncommon diseases.

While we admit the imaginable of SLNO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.